Infant Formula Quality & Corporate Responsibility

Why Infant Formula Demands Board-Level Attention

Infant formula is unlike any other dairy category. The consumer is an infant, often using formula as the sole source of nutrition. The regulatory framework is more demanding (Codex Alimentarius, EU 2016/127, FDA, China SAMR, GCC and country-specific). The customer is the parent, but the regulator is the state, and the reputational counter-party is media and social media that respond to incidents within hours.

Industry incidents - Cronobacter contamination in 2022, melamine adulteration in 2008, periodic recalls for foreign body and labelling issues - have demonstrated that failure modes are real, that they affect every type of manufacturer (multinational, mid-market, owner-operated), and that the financial and reputational consequences run into hundreds of millions where major brands are involved. Insurance does not fully recover the loss. Brand recovery, where it occurs at all, takes years.

That risk profile means infant formula manufacturers need quality oversight at board level, not just operational level. The question for directors is whether their company's quality systems would withstand independent scrutiny - not whether they are formally documented, but whether they are genuinely effective in practice.

What Independent Review Covers

The "All Due Diligence" Standard

The legal and regulatory standard for infant formula is not perfection - it is "all due diligence", or its equivalent in other jurisdictions. The standard asks: did the company do everything reasonably possible to prevent harm? That is a higher bar than "did we follow procedure" and a lower bar than "did the incident occur".

Meeting the due diligence standard requires that quality systems are genuinely effective, that the company learns from near-misses and external industry incidents, that quality investment is sustained even when commercial pressure is high, and that leadership creates a culture where escalation is welcomed rather than punished. These are board-level questions, not just QA-department questions.

Independent Quality Governance for Investor-Backed Businesses

For PE and family-office-backed infant formula businesses, investor expectations on quality governance have risen substantially. Investors increasingly require independent quality oversight at board level, separate from the operational quality function. This protects investor reputation, supports exit valuation, and provides early warning of quality risks before they become commercial problems.

We can take advisory or non-executive director roles in this capacity, on a case-by-case basis, where the engagement does not conflict with our other client work.

Frequently Asked Questions

What is infant formula corporate responsibility?

The board-level and executive-level obligation to ensure that infant formula products are safe, that quality systems are genuinely effective rather than merely documented, that traceability and recall capability are real, and that the company exercises proper due diligence at every step of the supply chain. The standard is not "we followed the regulations" but "we did everything reasonably possible".

Why infant formula specifically?

Because infant formula is fed to the most vulnerable consumers - new-borns, infants and young children, often as the sole nutrient source. Failure modes that would be commercially serious in other categories become potentially fatal in infant formula. The regulatory bar is correspondingly higher, customer requirements are stricter, and reputational damage from incidents is faster and more durable than in any other dairy category.

What does the review cover?

Quality systems (HACCP, prerequisite programmes, environmental monitoring), supplier audit and approval, microbiological standards, traceability and recall testing, batch release protocols, complaint handling, regulatory affairs, and board and executive governance over each of these. Output is a written assessment with specific gaps identified and prioritised remediation.

Do you act as Chief Ethics Officer or independent director?

On a case-by-case basis we can take advisory or non-executive director roles where the company needs independent quality and ethics oversight at board level - particularly relevant for investor-backed infant formula businesses where buyers expect to see independent quality governance. Engagement structured to avoid conflict with our other client work.

How does this relate to investor due diligence?

For investors in infant formula businesses, the quality system review is one of the most consequential due diligence questions. We provide pre-investment quality assessment, post-investment governance support, and ongoing board-level quality oversight. See our due diligence page for the broader framework.

What is your fee model?

Day rate plus expenses for one-off reviews. Retainer arrangements for ongoing board advisory or quality oversight roles. No success fees, no contingent arrangements. Independence is the entire value proposition.

Further reading: John Watson publishes articles on dairy industry topics on LinkedIn — from infant formula safety and milk supply to plant design, yield improvement and dairy commodity outlook. Browse all articles by John Watson on LinkedIn →

See our related infant formula production, expert witness, due diligence, supply chain evaluation and non-executive directorship pages, or browse all consultancy services.